MICHAEL PAUL GIMNESS: Open Payments
NPI 1518958222 · PLANT CITY, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,007 in 93 payments from 18 companies in 2025. Trend: 2023 $1,516 · 2024 $1,713 · 2025 $2,007
Food & beverage: $1,919Education: $88
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 19 | $471 |
| Astellas Pharma US Inc | 7 | $255 |
| AstraZeneca Pharmaceuticals LP | 13 | $236 |
| Amgen Inc. | 15 | $235 |
| ABBVIE INC. | 8 | $157 |
| GlaxoSmithKline, LLC. | 6 | $119 |
| PFIZER INC. | 5 | $98 |
| Lilly USA, LLC | 4 | $87 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $67 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $66 |
Products named: Ozempic, Veozah, AIRSUPRA, OTEZLA, JARDIANCE, VRAYLAR, Wegovy, TRELEGY ELLIPTA.
Industry payments across FL — which companies pay providers there.
